Top Markets
#1 MarsCoin MarsCoin +37.64%
#2 Palladium Network Palladium Network +27.94%
#3 Siren Siren +26.04%
#4 Status Status +24.20%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#6 BankrCoin BankrCoin +15.09%
#7 ICON ICON +15.04%
#8 Useless Coin Useless Coin +11.93%
#9 Ankr Network Ankr Network +11.88%
#10 Bedrock Bedrock +11.87%
Coin of the day
MarsCoin MarsCoin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Rang in Aktien #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Aktienkurs
$0.28078542
Marktkapitalisierung
$199.87M
Veränderung (1 Tag)
-0.34%
Veränderung (1 Jahr)
-10.19%
Land
TW
Handel TaiGen Biopharmaceuticals Holdings Limited (4157)

Kategorie

Healthcare
P/S-Verhältnis für TaiGen Biopharmaceuticals Holdings Limited (4157)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von TaiGen Biopharmaceuticals Holdings Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für TaiGen Biopharmaceuticals Holdings Limited von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH